A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Unverricht-Lundborg syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 15 Dec 2015 Results from this and other trial (see profile 16138) published in the Epilepsia
    • 19 Dec 2007 New trial record.
    • 14 Dec 2007 Full results of the analysis of secondary endpoints are expected by the second quarter of 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top